TrialEvaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
Trial details
- Registry ID
- NCT04984278
- Phase
- Phase 3
Drug research
Nabiximols
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as GW-1000-02; Sativex
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisNCT04984278 | Jazz Pharmaceuticals | Phase 3 | Terminated | 2022-11-11Actual |
| Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple SclerosisNCT04203498 | Jazz Pharmaceuticals | Phase 3 | Terminated | 2023-02-10Actual |
| Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisNCT04657666 | Jazz Pharmaceuticals | Phase 3 | Completed | 2022-05-04Actual |
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
Trial details
- Registry ID
- NCT04203498
- Phase
- Phase 3
Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
Trial details
- Registry ID
- NCT04657666
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |